Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib

ConclusionSubstantial nonadherence (< 90%) to nilotinib was rare and nilotinibCmin were generally above the therapeutic target. Lack of response in our group of patients was not related to nonadherence or inadequateCmin. Nevertheless, a considerable number of patients experienced difficulties in adhering to the twice daily fasted dosing regimen, emphasizing the importance of continuous support of medication adherence in CML.Clinical trial registrationNTR3992 (Netherlands Trial Register,www.trialregister.nl)
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research